CTI is developing medicines to help treat your cancer while maintaining your quality of life.
Pixantrone is marketed by CTI in the EU as Pixuvri®.Summary of Product Characteristics and Package Insert
Learn about our potential treatments for non-Hodgkin Lymphoma.See Phase 3 Pipeline
Learn about our potential treatments for Acute Myeloid Leukemia (AML), Myelodysplasia (MDS).See Phase 1 Pipeline
Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
Integrated Safety and Efficacy Analysis of Phase 2 Clinical Trials of Pacritinib in Patients with Myelofibrosis and Low Platelet Counts Presented at ASH Annual Meeting
BAXTER AND CELL THERAPEUTICS ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE PACRITINIBLearn more
Our late-stage development pipeline addresses a full complement of blood-related cancers.learn about our oncology pipeline